Christopher Viehbacher

Reata CEO Warren Huff

Biogen To Acquire Plano-Based Biotech Reata Pharmaceuticals

by | Jul 28, 2023
Founded in 2002, rare disease drugmaker Reata has made significant advances in therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. The company's FDA-approved SKYCLARYS is the first and only approved treatment in the U.S. for Friedreich’s ataxia, a genetic nervous system disorder.